ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

OPGX Optigenex Inc (CE)

0.0003
0.00 (0.00%)
17 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Optigenex Inc (CE) USOTC:OPGX OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.0003 11 01:00:00

Optigenex Inc. Announces Supply And License Agreement With Suracell Inc. To Utilize The AC-11(R) Trademark And Technology For Or

21/10/2009 2:00pm

PR Newswire (US)


Optigenex (CE) (USOTC:OPGX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Optigenex (CE) Charts.
Company plans to market dietary supplements under the brand name Suracell with AC-11(R) (Financial terms were not disclosed). NEW YORK, Oct. 21 /PRNewswire-FirstCall/ -- Optigenex Inc. (Pinksheets: OPGX) announced today the signing of a Supply and Trademark License Agreement with Suracell Inc. to provide its patented ingredient AC-11(R) for use in a focused nutritional and age management dietary supplement program. The agreement coupled with Suracell's marketing plans will provide another platform to introduce Optigenex's technology under the registered trademark AC-11(R) to health conscious consumers in the United States, Canada and South Korea. Beginning in January 2010, Suracell will be marketing a specific dietary supplement regimen. Participants will complete lifestyle questionnaires and will be asked to provide specimens for testing of key bio markers that will form the basis for a focused nutritional supplement program utilizing the diverse line of Suracell formulated products with AC-11(R). All-natural, herbal-extracted and patented AC-11(R) is marketed by over 100 manufacturers and marketing companies in Japan, Europe, the Middle East, the United States and Canada in a variety of anti-aging cosmetic, dietary supplement and advanced DNA care products. Daniel Zwiren, president and CEO of Optigenex Inc. said, "We are excited to add Suracell to our family of customers. We believe Suracell's scientifically validated formulas are an ideal fit for the unique properties of AC-11(R), including natural DNA repair, immune enhancement and inhibition of pro-inflammatory agents. The licensing relationship we are entering into today will allow both companies to expand significantly their respective businesses and market penetration. A Suracell spokesperson added, "The addition of AC -11(R) to the proprietary customized Suracell formulations gives us a product line unparalleled in its potential benefits to its customers. The evolving science surrounding AC 11(R) promises a very exciting future for our product offerings. About Suracell Inc.: Suracell Inc. provides personal genetic health programs formulated to measure, assess treat and monitor the body's individual genetic needs. The testing and analysis programs are designed to pinpoint deficiencies and damage in an individual's DNA and provide personalized recommended protocols consisting of specially formulated nutraceuticals and positive lifestyle choices. About Optigenex Inc.: Optigenex Inc. (http://www.optigenex.com/) is a formulator, distributor and provider of proprietary next generation skin care, supplements and bulk ingredient featuring AC-11(R) (formerly known as C-MED-100(R)), a patented compound, as its core technology. AC- 11(R) is the bioactive, water-soluble form of the medicinal herb Uncaria tomentosa. For more information about Optigenex please email the company at: . * The statements made in this press release have not been evaluated by the Food and Drug Administration. The products mentioned in this release are not intended to diagnose, treat, cure or prevent any disease. CONTACT: For more information about Optigenex please email the company at: DATASOURCE: Optigenex Inc. CONTACT: For more information about Optigenex please email the company at:

Copyright

1 Year Optigenex (CE) Chart

1 Year Optigenex (CE) Chart

1 Month Optigenex (CE) Chart

1 Month Optigenex (CE) Chart